Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Kanuma Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Kanuma (sebelipase alfa) Coverage Criteria

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    CareSource Arkansas PASSE medical prior authorization coverage for Kanuma (sebelipase alfa) in members with lysosomal acid lipase deficiency, including initial authorization and continued treatment.

    Policy Summary
    PayerCareSource
    PolicyKanuma (sebelipase alfa) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative reference update only
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain medical prior authorization for Kanuma (sebelipase alfa).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 monthMinimum age for initial authorization
    6 monthsInitial authorization duration
    12 monthsReauthorization duration
    5 mg/kgHighest permitted infant dose
    2Diagnostic confirmation methods

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following requirements are met:

    ALL of the following

    • Member is at least 1 month of age.
    • Medication is prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist.
    • ONE of the following diagnostic confirmation methods

      • Deficient LAL enzyme activity confirmed by assay.
      • Biallelic pathogenic mutations of the LIPA gene identified by genetic testing.
    • At least ONE clinical feature of LAL deficiency

      • Dyslipidemia.
      • Elevated transaminases (ALT or AST).
      • Impaired growth or failure to thrive.
      • Malabsorption.
      • Hepatomegaly.
      • Adrenal calcification in Wolman's disease.
      • Advanced liver disease.
    • Dosage is within the applicable limits: infants with rapidly progressive LAL-D within the first 6 months of life receive 1 mg/kg once weekly by IV infusion; if clinical response is suboptimal, the dose may increase to 3 mg/kg once weekly and then to 5 mg/kg once weekly if needed; pediatric and adult members receive 1 mg/kg by IV infusion every other week, with an increase to 3 mg/kg every other week if clinical response is suboptimal.

    ALL of the following

    • All initial authorization requirements are met.
    • Authorization is limited to 6 months.

    Continuation Therapy

    Covered for reauthorization when ALL of the following requirements are met:

    ALL of the following

    • Chart notes document a positive clinical response to treatment, such as improvement in lipid profile (LDL-c or triglycerides), liver biomarkers (ALT or AST), liver volume, or growth/weight z-scores in pediatric members.
    • Authorization is limited to an additional 12 months.

    Conditions or indications not listed in this document are excluded from medical necessity consideration. For any other indication, please refer to the Off-Label policy.

    CareSource considers Kanuma (sebelipase alfa) not medically necessary for the treatment of conditions that are not listed in this document.

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Medical prior authorization is required before Kanuma (sebelipase alfa) is covered under the medical benefit.

    Prior Authorization

    Initial Authorization Requirements

    Initial authorization requires that the member meet all clinical criteria for confirmed Lysosomal Acid Lipase (LAL) deficiency and have an appropriate specialist involved in prescribing or consultation.

    • Member is at least 1 month of age.
    • Kanuma is prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist.
    • LAL deficiency is confirmed by deficient LAL enzyme activity assay or identification of biallelic pathogenic LIPA gene mutations.
    • Member demonstrates at least one clinical feature of LAL deficiency, such as dyslipidemia, elevated ALT or AST, impaired growth or failure to thrive, malabsorption, hepatomegaly, adrenal calcification in Wolman's disease, or advanced liver disease.

    Clinical Background

    Lysosomal acid lipase deficiency is a genetic lysosomal storage disorder caused by deficient or absent lysosomal acid lipase activity. The resulting lipid accumulation can affect organs including the liver, spleen, intestine, and blood vessel walls, and may lead to dyslipidemia, accelerated atherosclerosis, liver fibrosis or cirrhosis, malabsorption, and growth failure. Kanuma (sebelipase alfa) is a recombinant human lysosomal acid lipase enzyme replacement therapy that addresses the underlying enzyme deficiency.

    Definitions

    Wolman disease
    PhenotypeEarly infantile-onset form of lysosomal acid lipase deficiency
    SeverityMore severe and rapidly progressive than other LAL deficiency phenotypes
    Expected survival without treatmentSurvival is not expected beyond infancy
    Cholesterol ester storage disease (CESD)
    PhenotypeChildhood- or adult-onset form of lysosomal acid lipase deficiency
    Clinical presentationMore variable than the early infantile-onset phenotype
    Treatment benefit

    Initial Therapy Criteria

    Kanuma Initial Authorization

    Initial Kanuma authorization requires all clinical, diagnostic, specialist, and dosing requirements below.

    Kanuma initial authorization

    • Minimum age: Member is at least 1 month of age.>= 1 month
    • Prescriber or consultant: Medication is prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist.
    • Confirmed LAL deficiency

      • Enzyme assay: Deficient LAL enzyme activity is demonstrated by assay.

    Continuation Criteria

    Kanuma Reauthorization

    Kanuma reauthorization requires documented positive clinical response.

    Positive response to treatment: Chart notes document improvement in at least one treatment-related measure: lipid profile, including LDL-C or triglycerides; liver biomarkers, including ALT or AST; liver volume; or growth or weight z-scores in a pediatric member.

    Reauthorization is approved for an additional 12 months when this requirement is met.

    Quantity and Dosing Limits

    Kanuma (sebelipase alfa) — infant dosing
    PopulationInfants with rapidly progressive LAL deficiency within the first 6 months of life
    Starting dose1 mg/kg once weekly by intravenous infusion
    EscalationIf clinical response is suboptimal, increase to 3 mg/kg once weekly and, if needed, further to 5 mg/kg once weekly
    Kanuma (sebelipase alfa) — pediatric and adult dosing
    PopulationPediatric and adult patients with LAL deficiency
    Starting dose1 mg/kg by intravenous infusion every other week
    Escalation
    Policy Summary
    PayerCareSource
    PolicyKanuma (sebelipase alfa) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative reference update only
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain medical prior authorization for Kanuma (sebelipase alfa).
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity and Dosing Limits
    Billing Rule

    Initial Dosing and Authorization Duration

    The requested dose must follow the applicable age-based regimen and quantity limits. When all initial requirements are met, authorization is granted for 6 months.

    • Infants with rapidly progressive LAL deficiency within the first 6 months of life: 1 mg/kg by IV infusion once weekly; may increase to 3 mg/kg once weekly and then 5 mg/kg once weekly if clinical response is suboptimal.
    • Pediatric and adult LAL deficiency: 1 mg/kg by IV infusion every other week; may increase to 3 mg/kg every other week if clinical response is suboptimal.
    Documentation Required

    Initial Authorization Documentation

    Submit initial authorization documentation that establishes eligibility and supports the clinical need for Kanuma.

    • Member's age, confirming the member is at least 1 month old.
    • Prescriber specialty or documentation that the medication is prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist.
    • Confirmed LAL deficiency, including the diagnostic method: deficient LAL enzyme activity assay or biallelic pathogenic LIPA gene mutations identified through genetic testing.
    • Clinical documentation of at least one relevant LAL deficiency feature, including dyslipidemia, elevated ALT or AST, impaired growth or failure to thrive, malabsorption, hepatomegaly, adrenal calcification in Wolman's disease, or advanced liver disease.
    • Requested dose and regimen consistent with the applicable infant, pediatric, or adult dosing requirements.
    Documentation Required

    Reauthorization Requirements

    Reauthorization requires chart documentation demonstrating a positive clinical response to Kanuma. When this requirement is met, authorization may be extended for an additional 12 months.

    • Document improvement in one or more relevant measures, such as LDL-C or triglycerides, ALT or AST, liver volume, or pediatric growth/weight z-scores.
    Documentation Required

    Reauthorization Response Documentation

    Reauthorization requests must include chart notes documenting the member's positive clinical response to treatment.

    • Include objective response documentation, such as an improved lipid profile, improved liver biomarkers, reduced liver volume, or improved growth/weight z-scores when applicable for pediatric members.
    Denial Risk

    Unlisted Indication

    Kanuma is not medically necessary for conditions or indications not listed in this policy. For other indications, refer to the applicable Off-Label policy.

    Kanuma has proven benefits for patients with cholesterol ester storage disease
    Enzyme replacement therapy (ERT)
    DefinitionA treatment that replaces deficient lysosomal acid lipase activity
    MedicationKanuma (sebelipase alfa) is a recombinant human lysosomal acid lipase enzyme replacement therapy
    MechanismCatalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to break them down
  1. Genetic testing: Biallelic pathogenic mutations of the LIPA gene are identified by genetic testing.
  2. Clinical manifestation

    • Dyslipidemia.
    • Elevated transaminases: Elevated ALT or AST.
    • Impaired growth or failure to thrive.
    • Malabsorption.
    • Hepatomegaly.
    • Adrenal calcification in Wolman's disease.
    • Advanced liver disease.
  3. Age-specific dosing

    • Infant dosing: For infants with rapidly progressive LAL deficiency within the first 6 months of life: starting dose 1 mg/kg once weekly via IV infusion; if clinical response is suboptimal, escalation to 3 mg/kg once weekly and further to 5 mg/kg once weekly if needed is allowed.
    • Pediatric and adult dosing: For pediatric and adult LAL deficiency: 1 mg/kg by IV infusion every other week; if clinical response is suboptimal, escalation to 3 mg/kg every other week is allowed.
  4. If clinical response is suboptimal, increase to 3 mg/kg every other week